Retinal thickness in Alzheimer's disease: A systematic review and meta-analysis

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 6, Issue , 2017, Pages 162-170

  den Haan, Jurre ^a   Verbraak, Frank D ^b,c   Visser, Pieter Jelle ^a,d   Bouwman, Femke H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Alzheimer's disease (AD); Biomarkers; Eye; Meta analysis; Mild cognitive impairment (MCI); Optical coherence tomography (OCT); Retinal thickness

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; HUMAN; MACULAR THICKNESS; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINAL NERVE FIBER LAYER THICKNESS; RETINAL THICKNESS; SYSTEMATIC REVIEW (TOPIC);

EID: 85013647400     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2016.12.014     Document Type: Article

References (50)

1. [1] Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
2. [2] McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 263–269.
3. [3] Jack, C.R., Holtzman, D.M., Biomarker modeling of Alzheimer's disease. Neuron 80 (2013), 1347–1358.
4. [4] Reardon, S., Antibody drugs for Alzheimer's show glimmers of promise. Nature 523 (2015), 509–510.
5. [5] Petzold, A., de Boer, J.F., Schippling, S., Vermersch, P., Kardon, R., Green, A., et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 9 (2010), 921–932.
6. [6] Yu, J.G., Feng, Y.F., Xiang, Y., Huang, J.H., Savini, G., Parisi, V., et al. Retinal nerve fiber layer thickness changes in Parkinson disease: a meta-analysis. PLoS One, 9, 2014, e85718.
7. [7] Pillai, J.A., Bermel, R., Bonner-Jackson, A., Rae-Grant, A., Fernandez, H., Bena, J., et al. Retinal nerve fiber layer thinning in Alzheimer's disease: a case-control study in comparison to normal aging, Parkinson's disease, and non-Alzheimer's dementia. Am J Alzheimers Dis Other Demen 31 (2016), 430–436.
8. [8] La Morgia, C., Ross-Cisneros, F.N., Koronyo, Y., Hannibal, J., Gallassi, R., Cantalupo, G., et al. Melanopsin retinal ganglion cell loss in Alzheimer's disease. Ann Neurol 79 (2016), 90–109.
9. [9] Salobrar-Garcia, E., Hoyas, I., Leal, M., de Hoz, R., Rojas, B., Ramirez, A.I., et al. Analysis of retinal peripapillary segmentation in early Alzheimer's disease patients. Biomed Res Int, 2015, 2015, 636548.
10. [10] Eraslan, M., Çerman, E., Çekiç, O., Balci, S., Dericioğlu, V., Sahin, Ö., et al. Neurodegeneration in ocular and central nervous systems: optical coherence tomography study in normal-tension glaucoma and Alzheimer disease. Turk J Med Sci 45 (2015), 1106–1114.
11. [11] Güneş, A., Demirci, S., Tök, L., Tök, Ö., Demirci, S., Evaluation of retinal nerve fiber layer thickness in Alzheimer disease using spectral-domain optical coherence tomography. Turk J Med Sci 45 (2015), 1094–1097.
12. [12] Liu, D., Zhang, L., Li, Z., Zhang, X., Wu, Y., Yang, H., et al. Thinner changes of the retinal nerve fiber layer in patients with mild cognitive impairment and Alzheimer's disease. BMC Neurol 15 (2015), 1–5.
13. [13] Oktem, E.O., Derle, E., Kibaroglu, S., Oktem, C., Akkoyun, I., Can, U., The relationship between the degree of cognitive impairment and retinal nerve fiber layer thickness. Neurol Sci 36 (2015), 1141–1146.
14. [14] Cheung, C.Y., Ong, Y.T., Hilal, S., Ikram, M.K., Low, S., Ong, Y.L., et al. Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 45 (2015), 45–56.
15. [15] Gao, L., Liu, Y., Li, X., Bai, Q., Liu, P., Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer's disease. Arch Gerontol Geriatr 60 (2015), 162–167.
16. [16] Bambo, M.P., Garcia-Martin, E., Gutierrez-Ruiz, F., Pinilla, J., Perez-Olivan, S., Larrosa, J.M., et al. Analysis of optic disc color changes in Alzheimer's disease: a potential new biomarker. Clin Neurol Neurosurg 132 (2015), 68–73.
17. [17] Larrosa, J.M., Garcia-Martin, E., Bambo, M.P., Pinilla, J., Polo, V., Otin, S., et al. Potential new diagnostic tool for Alzheimer's disease using a linear discriminant function for Fourier domain optical coherence tomography. Invest Ophthalmol Vis Sci 55 (2014), 3043–3051.
18. [18] Ascaso, F.J., Cruz, N., Modrego, P.J., Lopez-Anton, R., Santabarbara, J., Pascual, L.F., et al. Retinal alterations in mild cognitive impairment and Alzheimer's disease: an optical coherence tomography study. J Neurol 261 (2014), 1522–1530.
19. [19] Polo, V., Garcia-Martin, E., Bambo, M.P., Pinilla, J., Larrosa, J.M., Satue, M., et al. Reliability and validity of Cirrus and Spectralis optical coherence tomography for detecting retinal atrophy in Alzheimer's disease. Eye (Lond) 28 (2014), 680–690.
20. [20] Gharbiya, M., Trebbastoni, A., Parisi, F., Manganiello, S., Cruciani, F., D'Antonio, F., et al. Choroidal thinning as a new finding in Alzheimer's Disease: Evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimers Dis 40 (2014), 907–917.
21. [21] Kromer, R., Serbecic, N., Hausner, L., Froelich, L., Aboul-Enein, F., Beutelspacher, S.C., Detection of retinal nerve fiber layer defects in Alzheimer's disease using SD-OCT. Front Psychiatry, 5, 2014, 22.
22. [22] Moreno-Ramos, T., Benito-Leon, J., Villarejo, A., Bermejo-Pareja, F., Retinal nerve fiber layer thinning in dementia associated with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease. J Alzheimers Dis 34 (2013), 659–664.
23. [23] Marziani, E., Pomati, S., Ramolfo, P., Cigada, M., Giani, A., Mariani, C., et al. Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer's disease using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 54 (2013), 5953–5958.
24. [24] Kirbas, S., Turkyilmaz, K., Anlar, O., Tufekci, A., Durmus, M., Retinal nerve fiber layer thickness in patients with Alzheimer disease. J Neuroophthalmol 33 (2013), 58–61.
25. [25] Moschos, M.M., Markopoulos, I., Chatziralli, I., Rouvas, A., Papageorgiou, S.G., Ladas, I., et al. Structural and functional impairment of the retina and optic nerve in Alzheimer's disease. Curr Alzheimer Res 9 (2012), 782–788.
26. [26] Kesler, A., Vakhapova, V., Korczyn, A.D., Naftaliev, E., Neudorfer, M., Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg 113 (2011), 523–526.
27. [27] Lu, Y., Li, Z., Zhang, X., Ming, B., Jia, J., Wang, R., et al. Retinal nerve fiber layer structure abnormalities in early Alzheimer's disease: evidence in optical coherence tomography. Neurosci Lett 480 (2010), 69–72.
28. [28] Paquet, C., Boissonnot, M., Roger, F., Dighiero, P., Gil, R., Hugon, J., et al. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 420 (2007), 97–99.
29. [29] Berisha, F., Feke, G.T., Trempe, C.L., McMeel, J.W., Schepens, C.L., Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci 48 (2007), 2285–2289.
30. [30] Iseri, P.K., Altinas, O., Tokay, T., Yuksel, N., Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol 26 (2006), 18–24.
31. [31] Parisi, V., Restuccia, R., Fattapposta, F., Mina, C., Bucci, M.G., Pierelli, F., Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol 112 (2001), 1860–1867.
32. [32] Wan, X., Wang, W., Liu, J., Tong, T., Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol, 14, 2014, 135.
33. [33] Whiting, P., Rutjes, A.W., Reitsma, J.B., Bossuyt, P.M., Kleijnen, J., The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol, 3, 2003, 25.
34. [34] Forte, R., Cennamo, G.L., Finelli, M.L., de Crecchio, G., Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume. Eye (Lond) 23 (2009), 2071–2078.
35. [35] Bouwman, F.H., Schoonenboom, N.S., Verwey, N.A., van Elk, E.J., Kok, A., Blankenstein, M.A., et al. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 30 (2009), 1895–1901.
36. [36] Yoneda, S., Hara, H., Hirata, A., Fukushima, M., Inomata, Y., Tanihara, H., Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases. Jpn J Ophthalmol 49 (2005), 106–108.
37. [37] Sadun, A.A., Bassi, C.J., Optic nerve damage in Alzheimer's disease. Ophthalmology 97 (1990), 9–17.
38. [38] de Voogd, S., Ikram, M.K., Wolfs, R.C., Jansonius, N.M., Hofman, A., de Jong, P.T., Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology 112 (2005), 1487–1493.
39. [39] Wolfs, R.C., Borger, P.H., Ramrattan, R.S., Klaver, C.C., Hulsman, C.A., Hofman, A., et al. Changing views on open-angle glaucoma: definitions and prevalences—The Rotterdam Study. Invest Ophthalmol Vis Sci 41 (2000), 3309–3321.
40. [40] Bayer, A.U., Ferrari, F., Erb, C., High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol 47 (2002), 165–168.
41. [41] Lin, I.C., Wang, Y.H., Wang, T.J., Wang, I.J., Shen, Y.D., Chi, N.F., et al. Glaucoma, Alzheimer's disease, and Parkinson's disease: an 8-year population-based follow-up study. PLoS One, 9, 2014, e108938.
42. [42] Ou, Y., Grossman, D.S., Lee, P.P., Sloan, F.A., Glaucoma, Alzheimer disease and other dementia: a longitudinal analysis. Ophthalmic Epidemiol 19 (2012), 285–292.
43. [43] Keenan, T.D., Goldacre, R., Goldacre, M.J., Associations between primary open angle glaucoma, Alzheimer's disease and vascular dementia: record linkage study. Br J Ophthalmol 99 (2015), 524–527.
44. [44] Cesareo, M., Martucci, A., Ciuffoletti, E., Mancino, R., Cerulli, A., Sorge, R.P., et al. Association between Alzheimer's disease and glaucoma: a study based on Heidelberg retinal tomography and frequency doubling technology perimetry. Front Neurosci, 9, 2015, 479.
45. [45] Ossenkoppele, R., Jansen, W.J., Rabinovici, G.D., Knol, D.L., van der Flier, W.M., van Berckel, B.N., et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313 (2015), 1939–1949.
46. [46] van Dijk, H.W., Verbraak, F.D., Kok, P.H., Stehouwer, M., Garvin, M.K., Sonka, M., et al. Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci 53 (2012), 2715–2719.
47. [47] Snyder, P.J., Johnson, L.N., Lim, Y.Y., Santos, C.Y., Alber, J., Maruff, P., et al. Nonvascular retinal imaging markers of preclinical Alzheimer's disease. Alzheimers Dement (Amst) 4 (2016), 169–178.
48. [48] Lehmann, M., Koedam, E.L., Barnes, J., Bartlett, J.W., Barkhof, F., Wattjes, M.P., et al. Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. Neurobiol Aging 34 (2013), 73–82.
49. [49] Clerx, L., Visser, P.J., Verhey, F., Aalten, P., New MRI markers for Alzheimer's disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements. J Alzheimers Dis 29 (2012), 405–429.
50. [50] van de Pol, L.A., Hensel, A., van der Flier, W.M., Visser, P.J., Pijnenburg, Y.A., Barkhof, F., et al. Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. J Neurol Neurosurg Psychiatry 77 (2006), 439–442.